

The use of cluster analysis to identify factors that influence the establishment of Health Technologies Assessment (HTA) agencies

Yolanda Bravo Vergel, Brian Ferguson and Cynthia Iglesias

*Centre for Health Economics, University of York
Humber & Yorkshire Observatory of Public Health*

iHEA, Barcelona 10-13 July 2005

Aims

- Provide an overview and simplified classification of the HTA organisations present in the OECD.
- To investigate the factors that can influence the setting up of Health Technology Assessment (HTA) agencies across OECD countries.

Background

- Phenomenon emergence HTA organisations early 90s: partially in line with:
 - the growth of specialized agencies Western countries
 - 2nd phase debate priority-setting in health care
- Delegation decision-making powers to arm's-length agencies (Majone 1986,87):
 - making credible policy commitments in controversial / unpopular decisions
 - need for expertise highly complex or technical matters
 - free public administration from partisan politics
- “Responsible for assessment new/existing healthcare technologies as to their effectiveness, appropriateness, and/or cost-effectiveness” (INAHTA).

Data sources

- OECD Health Database (2004)
- INAHTA database of HTA country profiles [35 members, <http://www.inahta.org>, May 2005].
- Literature review, mainly HiT country profiles by the European Observatory on Health Care Systems and OECD reports.

Framework of variables

- (1) Number HTA agencies
- (2) Public health expenditure (% GDP)
- (3) Public expenditure on pharmaceuticals (% GDP)
- (4) Form of health care decentralisation
[Collins's definition (1994)]
- (5) Type of health care system
[Gordon (1988), Saltman et al. (2000, 2001) typologies]
- (6) Principal shared-rule arrangement in the country
(unitary - federal political system)
[Elazar (1994) and Watts (1999) classification]

Table 1. Parameters used in the cluster and discriminant analysis

Country	Agencies	No. INAHTA Agencies	Type of health care system	Decentralisation health care system	Form political decentralisation	Public health expenditure (%GDP)	Public expenditure on pharmaceuticals (%GDP)
Australia	ASERNIP, MSAC	2	SHI	Devolution	Federation	6.2	0.7
Austria	ITA	1	SHI	Devolution	Federation	5.4	0.9
Belgium	KCE	1	SHI	Deconcentration	Fed.arrang.	6.5	0.7
Canada	AETMIS, AHFMR, CCOHTA	3	SHI	Devolution	Federation	6.7	0.6
Czech Rep	-	1	SHI	Deconcentration	Unitary state	6.8	1.3
Denmark	DACEHTA, DSI	2	NHS	Devolution	Fed.arrang.	7.3	0.4
Finland	FinOHTA	1	NHS	Devolution	Fed.arrang.	5.5	0.6
France	HAS(ANAES), CEDIT	2	SHI	Centralised	Fed.arrang.	7.4	1.4
Germany	DAHTA@DIMDI	1	SHI	Devolution	Federation	8.6	1.2
Greece	-	0	NHS	Centralised	Unitary state	5	1
Hungary	HunHTA	1	Mixed	Deconcentration	Unitary state	5.5	1.3
Iceland	-	0	NHS	Deconcentration	Unitary state	8.3	0.8
Ireland	-	0	SHI	Deconcentration	Unitary state	5.5	0.7
Italy	-	0	NHS	Devolution	Fed.arrang.	6.4	1
Japan	-	0	SHI	Deconcentration	Fed.arrang.	6.4	1
Korea	-	0	Mixed	Centralised	Unitary state	3.2	0.7
Luxembourg	-	0	SHI	Centralised	Unitary state	5.3	0.6
México	-	0	Mixed	Deconcentration	Federation	2.8	0.1
Netherlands	CVZ, GR, ZonMW	3	SHI	Deconcentration	Fed.arrang.	5.5	0.6
New Zealand	NZHTA	1	Mixed	Deconcentration	Fed.arrang.	6.6	0.8
Norway	SMM	1	NHS	Devolution	Unitary state	7.4	0.4
Poland	-	0	Mixed	Deconcentration	Unitary state	4.4	0.7
Portugal	-	0	NHS	Deconcentration	Fed.arrang.	6.5	1.3
Slovakia	-	0	SHI	Deconcentration	Unitary state	5.1	1.8
Spain	AETS, AETSA, CAHTA, OSTEBA, UETS	5	NHS	Devolution	Federation	5.4	1.2
Sweden	CMT, SBU	2	NHS	Devolution	Unitary state	7.9	0.8
Switzerland	MTU/SFOPH	1	SHI	Devolution	Federation	6.5	0.8
Turkey	-	0	Mixed	Deconcentration	Unitary state	4.2	1
UK	CRD, IAHS, NCCHTA, NHS QIS, NHSC	5	NHS	Devolution	Fed.arrang.	6.4	0.7
USA	AHRQ, CMS, VATAP	3	Mixed	Devolution	Federation	6.6	0.4

Methods

Techniques of multivariate analysis: appropriate for situations when the random variation in several variables is to be studied simultaneously (Armitage 1971)

Cluster analysis:

- Classifies a set of observations into 2 or more unknown groups (minimize within-group variation, maximize between group variation).
- Groups are nested and represented in 2D dendrogram.
- Hierarchical or K-means?: no prior knowledge number groups and small sample (Everitt et al. 2001)
- *Proximity matrix* - method Euclidean distance

$$\text{Distance (A,B)} = \sqrt{\sum (A_i - B_i)^2}$$

- Linkage method: Average distance between groups

Methods

Linear discriminant function analysis:

- Find the linear combination of x's variables (*predicting variables*) which best discriminates among the different categories of the *grouping variable* ($n \Rightarrow 2$, defined by the clusters).
- *Fisher's linear function* - maximizes the ratio of the between-groups sum of squares (SSq) to the within groups SSq.
- Number of linear function = $K-1$ (grouping variable).
- F1, or highest latent root - gives the coefficients in the linear function that maximizes the ratio of SSq.
- F2 - function with the highest ratio of SSq, subject to the condition that is uncorrelated with F1.

Rescaled Distance Cluster Combine

C A S E		0	5	10	15	20	25
Label	Num	+-----+-----+-----+-----+-----+					
Poland	22	↓*↓↓↓↓↓					
Turkey	28	↓↗	□ ↓↓↓↓↓				
Korea	16	↓↓↓↓↓		↔			
Ireland	13	↓↓↓*↓		□ ↓↓↓↓↓			
Luxembourg	17	↓↓↓↗	↔		↔		
Greece	10	↓↓↓↓↓				□ ↓↓↓↓↓	
Slovakia	24	↓↓↓↓↓			↔	↔	
México	18	↓↓↓↓↓				↔	
Norway	21	↓↓↓*↓				↔	
Sweden	26	↓↓↓↗	□ ↓↓↓↓↓			↔	
Denmark	6	↓↓↓↓↓		□ ↓↓↓			□ ↓↓↓↓↓
Iceland	12	↓↓↓↓↓		□ ↓		↔	↔
Germany	9	↓↓↓↓↓		↔		↔	↔
Australia	1	↓↓↓		↔		↔	↔
Switzerland	27	↓↓↓↗		↔		↔	↔
Austria	2	↓↓↓↗	□ ↓↓↓↓↓		□ ↓↓↓↓↓		↔
Finland	7	↓↓↓↓↓	↔	↔			↔
Japan	15	↓↓↓*↓	□ ↓↓↓↓↓	↔			↔
Portugal	23	↓↓↓↗	□ ↓↓↓↓↓	↔	↔		↔
Italy	14	↓↓↓↓↓	↔	↔	↔		↔
Belgium	3	↓↓↓*↓	□ ↓	□ ↓			↔
New Zealand	20	↓↓↓↗	□ ↓	↔			↔
Czech Rep	5	↓↓↓↓↓	□ ↓↓↓	↔			↔
Hungary	11	↓↓↓↓↓		↔			↔
France	8	↓↓↓↓↓					↔
Spain	25	↓↓↓↓↓*↓					↔
UK	29	↓↓↓↓↓		□ ↓↓↓↓↓			↔
Canada	4	↓↓↓*↓	↓↓↓↓↓	↔			
USA	30	↓↓↓↗	□ ↓↓↓↓↓				
Netherlands	19	↓↓↓↓↓					

Results - cluster analysis

Group 1 (n= 8)

- Countries with no HTA agencies
- Public health expenditure < Average OECD
- Unitary states; centralised / deconcentrated

Group 2 (n=17)

- No. Agencies: 1 to 2 (exception: 4 no agency)
- Public health expenditure > Average OECD
- 50% NHS, 50% SHI
- Heterogeneous (traditional federal countries, Scandinavian...)

Group 3 (n=5)

- High number HTA agencies (≥ 3)
- Health expenditure average OECD
- All devolved systems (except Netherlands); 3 Federations

STANDARDIZED CANONICAL DISCRIMINANT FUNCTION COEFFICIENTES

	Function	
	1	2
PUBEXP	.861	.481
PUBPHARM	.116	.272
TYPESYST	-.062	.189
RULE ARRANGEMENT IN THE COUNTRY	.553	-.592
DECSYST	.316	-.195

MULTIVARIATE TESTS OF SIGNIFICANCE

Tests of Equality of Group Means

	Wilks' Lambda	F	df1	df2	Sig.
PUBEXP	.430	17.928	2	27	.000
PUBPHARM	.954	.650	2	27	.530
TYPESYST	.851	2.372	2	27	.112
RULE ARRANGEMENT IN THE COUNTRY	.701	5.765	2	27	.008
DECSYST	.623	8.166	2	27	.002

Wilks' Lambda

Test of Function(s)	Wilks' Lambda	Chi-square	df	Sig.
1 through 2	.251	34.551	10	.000
2	.844	4.245	4	.374

PREDICTED GROUP MEMBERSHIP AND MISCLASSIFICATIONS


Classification Results

			Predicted Group Membership			Total
			1	2	3	
Original	Count	1	8	0	0	8
		2	1	12	4	17
		3	0	0	5	5
	%	1	100.0	.0	.0	100.0
		2	5.9	70.6	23.5	100.0
		3	.0	.0	100.0	100.0


b. 83.3% of original grouped cases correctly classified.

ALL-GROUP SCATTER PLOT WITH MISCLASSIFIED CASES

Canonical Discriminant Functions



Canonical Discriminant Functions



Results - discriminant analysis

- Canonical correlation: About 70% variability in the discriminant scores is attributable to between-group differences for F1.
- Canonical coefficients - largest contributor is public expenditure, followed by political decentralisation & form of health care decentralisation.
- Degree of prediction of the 5 variables is high: 83% cases correctly classified.
- Scatter plot: F1 divides cases into two basic sections (group 1 on the left; groups 2+3 right).
- Discrimination power linear function 2 is not as good as F1 (blurred area between groups 2 and 3).

Conclusions

- Results suggest that a high level of public expenditure in health care and a decentralised decision-making context favour the setting up of HTA organisations.
- % Public expenditure in pharmaceuticals no relevant factor - counterintuitive
- 12 /18 countries with HTA agencies have devolved health decision-making authority to regional or local government



- local political accountability
- public awareness financial size problem

Can put pressure on governments to make a move towards explicit rationing

Discussion

- Cluster analysis results always considered with caution (certain degree subjectivity)
- Model provides a certain capacity prediction of future developments in the HTA area.
- This research shows the value of hierarchical cluster analysis in conjunction with discriminant function analysis for the classification of complex cases (See Nixon 2000).
- Normal distributional assumptions for traditional discriminant analysis are not satisfied. However, it is common practice to employ above procedures as a first analysis, since method produce satisfactory results even for scenarios where distributional assumptions cannot be met (Asparoukhov and Krzanowski 2001)

References

- Armitage P. 1971. *Statistical Methods in Medical Research*. Oxford: Blackwell Scientific Publications.
- Asparoukhov O. and Krzanowski W.J. 2001. A comparison of discriminant procedures for binary variables. *Computational Statistics and Data Analysis* 38:139-160.
- Collins Ch. 1994. *Management and Organization of Developing Health Systems.*, Oxford Medical Publications. Oxford: Oxford University Press.
- Elazar D.J. 1994. *Federal Systems of the World. A Handbook of Federal, Confederal and Autonomy Arrangements*. 2 ed. Essex: Longman Group Limited.
- Everitt B., Landau S., and Leese M. 2001. *Cluster Analysis*. 4th ed. London: Arnold Publishers.
- Gordon M.S. 1988. *Social Security Policies in Industrial Countries*. Cambridge: Cambridge University Press.
- Majone G. 1996. *Regulating Europe*. London: Routledge.
- Majone G. 1997. *Independent agencies and the delegation problem*. In *Political Institutions and Public Policy: Perspectives on European Decision Making*, edited by Steunenberg B. and Van Vught F. (Dordrecht: Kluwer Academic Publishers).
- Nixon J. *How does the UK NHS compare with European standards? A review of EU health care systems using hierarchical cluster analysis*. [182]. 2000b. York, The University of York. CHE Discussion Paper.
- Saltman R.B., Busse R., and Figueras J. 2002. *Social Health Insurance Countries in Western Europe*.
- Saltman R.B. and Figueras J. 2001. *European Health Care Reform. Analysis of Current Strategies*. Copenhagen: European Observatory on Health Care Systems.
- Watts R.L. 1999. *Comparing Federal Systems*. 2 ed. Kingston, Ontario.: McGill-Queen's University Press.